The Cost-Effectiveness of Bendamustine-Rituximab Versus Fludarabine-Rituximab for Patients with Indolent Non-Hodgkin’s Lymphoma (INHL) Who Have Progressed Following Treatment with Rituximab or a Rituximab-Containing Regimen in Colombia
Abstract
Authors
D. Bertwistle J. Munakata E Wehler V. Leyva J.G. Ariza C. Zambrano L. Gonzalez